Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan , July 15, 2020 — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.
( read original story …)


Search your Hotel